Shahram Majidi1,2, Alexis N Simpkins1, Richard Leigh1. 1. National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD. 2. Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY.
Abstract
BACKGROUND AND PURPOSE: Timely restoration of tissue-level cerebral blood flow is the goal of thrombolytic therapy in patients presenting with an acute ischemic stroke. We aimed to identify the incidence and predictors of reperfusion immediately following treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA). METHODS: This study included patients with acute ischemic stroke triaged using magnetic resonance imaging (MRI) with perfusion-weighted imaging (PWI) and treated with IV rt-PA who were subsequently enrolled in our natural history study and underwent repeat MRI with PWI approximately 2 hours posttreatment. Early reperfusion was defined as >80% decrease in the size of initial perfusion deficit on the 2 hours follow-up MRI. Demographics, stroke risk factors, presenting National Institutes of Health Stroke Scale score, and location of the thrombosis were compared between patients with and without early reperfusion. RESULTS: Of the 49 patients included in this study, 21 (43%) had early reperfusion. The mean age for patients with early reperfusion was significantly lower in comparison to the patients without early reperfusion (64 vs. 76, P = .01). The prevalence of hyperlipidemia was significantly lower among patients with early reperfusion (24% vs. 54%, P = .036). Patients with early reperfusion were less likely to have large-vessel occlusion (LVO) (internal carotid artery terminus or proximal middle cerebral artery) (24% vs. 50%, P = .06). In a multivariate analysis, the presence of an LVO was an independent predictor of lack of early reperfusion (OR [95%Cl]: .13 [.019-.89], P = .038). CONCLUSION: Early reperfusion was found in a substantial percentage of the patients treated with IV rt-PA. It was more common in patients without LVO. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
BACKGROUND AND PURPOSE: Timely restoration of tissue-level cerebral blood flow is the goal of thrombolytic therapy in patients presenting with an acute ischemic stroke. We aimed to identify the incidence and predictors of reperfusion immediately following treatment with intravenous recombinant tissue plasminogen activator (IV rt-PA). METHODS: This study included patients with acute ischemic stroke triaged using magnetic resonance imaging (MRI) with perfusion-weighted imaging (PWI) and treated with IV rt-PA who were subsequently enrolled in our natural history study and underwent repeat MRI with PWI approximately 2 hours posttreatment. Early reperfusion was defined as >80% decrease in the size of initial perfusion deficit on the 2 hours follow-up MRI. Demographics, stroke risk factors, presenting National Institutes of Health Stroke Scale score, and location of the thrombosis were compared between patients with and without early reperfusion. RESULTS: Of the 49 patients included in this study, 21 (43%) had early reperfusion. The mean age for patients with early reperfusion was significantly lower in comparison to the patients without early reperfusion (64 vs. 76, P = .01). The prevalence of hyperlipidemia was significantly lower among patients with early reperfusion (24% vs. 54%, P = .036). Patients with early reperfusion were less likely to have large-vessel occlusion (LVO) (internal carotid artery terminus or proximal middle cerebral artery) (24% vs. 50%, P = .06). In a multivariate analysis, the presence of an LVO was an independent predictor of lack of early reperfusion (OR [95%Cl]: .13 [.019-.89], P = .038). CONCLUSION: Early reperfusion was found in a substantial percentage of the patients treated with IV rt-PA. It was more common in patients without LVO. Published 2018. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Georgios Tsivgoulis; Aristeidis H Katsanos; Dimitris Mavridis; Anne W Alexandrov; Georgios Magoufis; Adam Arthur; Valeria Caso; Peter D Schellinger; Andrei V Alexandrov Journal: Ther Adv Neurol Disord Date: 2016-12-01 Impact factor: 6.570
Authors: Gregory W Albers; Vincent N Thijs; Lawrence Wechsler; Stephanie Kemp; Gottfried Schlaug; Elaine Skalabrin; Roland Bammer; Wataru Kakuda; Maarten G Lansberg; Ashfaq Shuaib; William Coplin; Scott Hamilton; Michael Moseley; Michael P Marks Journal: Ann Neurol Date: 2006-11 Impact factor: 10.422
Authors: William J Powers; Alejandro A Rabinstein; Teri Ackerson; Opeolu M Adeoye; Nicholas C Bambakidis; Kyra Becker; José Biller; Michael Brown; Bart M Demaerschalk; Brian Hoh; Edward C Jauch; Chelsea S Kidwell; Thabele M Leslie-Mazwi; Bruce Ovbiagele; Phillip A Scott; Kevin N Sheth; Andrew M Southerland; Deborah V Summers; David L Tirschwell Journal: Stroke Date: 2018-01-24 Impact factor: 7.914
Authors: Kenichi Oishi; Andreia Faria; Hangyi Jiang; Xin Li; Kazi Akhter; Jiangyang Zhang; John T Hsu; Michael I Miller; Peter C M van Zijl; Marilyn Albert; Constantine G Lyketsos; Roger Woods; Arthur W Toga; G Bruce Pike; Pedro Rosa-Neto; Alan Evans; John Mazziotta; Susumu Mori Journal: Neuroimage Date: 2009-06 Impact factor: 6.556
Authors: Leonard L L Yeo; Prakash Paliwal; Hock L Teoh; Raymond C Seet; Bernard P L Chan; Shen Liang; Narayanaswamy Venketasubramanian; Rahul Rathakrishnan; Aftab Ahmad; Kay W P Ng; Pei K Loh; Jonathan J Y Ong; Benjamin R Wakerley; Vincent F Chong; Girish Bathla; Vijay K Sharma Journal: JAMA Neurol Date: 2013-03-01 Impact factor: 18.302
Authors: Julio A Chalela; Dong-Wha Kang; Marie Luby; Mustapha Ezzeddine; Lawrence L Latour; Jason W Todd; Billy Dunn; Steven Warach Journal: Ann Neurol Date: 2004-01 Impact factor: 10.422